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A B S T R A C T
Background: Neuroimaging studies help us better understand the pathophysiology and symptoms of Parkinson's
disease (PD). In several of these studies, diffusion tensor imaging (DTI) was used to investigate structural
changes in cerebral tissue. Although data have been provided as regards to specific brain areas, a whole brain
meta-analysis is still missing.
Methods: We compiled 39 studies in this meta-analysis: 14 used fractional anisotropy (FA), 1 used mean dif-
fusivity (MD), and 24 used both indicators. These studies comprised 1855 individuals, 1087 with PD and 768
healthy controls. Regions of interest were classified anatomically (subcortical structures; white matter; cortical
areas; cerebellum). Our statistical analysis considered the disease effect size (DES) as the main variable; the
heterogeneity index (I2) and Pearson's correlations between the DES and co-variables (demographic, clinical and
MRI parameters) were also calculated.
Results: Our results showed that FA-DES and MD-DES were able to distinguish between patients and healthy
controls. Significant differences, indicating degenerations, were observed within the substantia nigra, the corpus
callosum, and the cingulate and temporal cortices. Moreover, some findings (particularly in the corticospinal
tract) suggested opposite brain changes associated with PD. In addition, our results demonstrated that MD-DES
was particularly sensitive to clinical and MRI parameters, such as the number of DTI directions and the echo time
within white matter.
Conclusions: Despite some limitations, DTI appears as a sensitive method to study PD pathophysiology and
severity. The association of DTI with other MRI methods should also be considered and could benefit the study of
brain degenerations in PD.
1. Introduction
Motor signs and symptoms of Parkinson's disease (PD) are a result of
the degeneration of large parts of the substantia nigra (SN). PD also
involves the degeneration of multiple neurotransmitter systems (e.g.
noradrenaline, serotonin, acetylcholine (Halliday et al., 2014)), which
are connected to non-motor disorders that can affect cognitive (Yarnall
et al., 2013; for a review, see Kudlicka et al., 2011) and neu-
ropsychiatric domains, such as cognitive impairment (leading to de-
mentia in most patients), depression, anhedonia, and apathy (for a re-
view, see Kaji and Hirata, 2011). It is currently thought that the pre-
symptomatic stages of PD are mostly associated with subcortical and
sympathetic nervous system degenerations (Hawkes et al., 2010).
Cortical lesions appear in later stages of the disease (Goedert et al.,
2013).
1.1. Magnetic Resonance Imaging in PD
As regards our knowledge of PD pathophysiology, recent neuroi-
maging methods make it possible to investigate anatomy and impact of
brain alterations, on the basis of functional, structural and diffusion
data acquisitions, three complementary techniques to assess brain
changes related to neurodegenerative diseases like PD. Resting-state
functional Magnetic Resonance Imaging (fMRI) can be used to study
brain connectivity and the alterations of functional networks. A recent
review of the literature provided interesting insights into the functional
alterations in PD (Prodoehl et al., 2014): mainly, PD induces functional
dysfunctions particularly in the sensorimotor, visual and basal ganglia
networks. It is reasonable to argue that fMRI data depends on several
parameters, such as the dopaminergic medication state (e.g., Tessitore
et al., 2012; Krajcovicova et al., 2012) or the fMRI acquisition
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parameters (e.g. Prodoehl et al., 2014). Concerning anatomical MRI,
voxel-based morphometry (VBM) can be used to study the volume of
gray matter (Ashburner and Friston, 2000). Recent VBM meta-analyses
demonstrated a cortical atrophy in PD patients in the left inferior
frontal gyrus, superior temporal gyrus, insula and parietal areas (for a
review, see Pan et al., 2012; Shao et al., 2014; (Yu et al., 2015), but also
in the left-sided parahippocampal gyrus, insula and superior temporal
gyrus in younger patients, as well as a correlation between disease
duration and motor impairment and gray matter reduction in the left
inferior frontal gyrus (Pan et al., 2012). While fMRI allows the study of
functional connectivity by assessing neuronal (dys)functioning related
to PD, structural MRI adds information regarding anatomical changes,
and particularly cortical lesions that are also involved in the disease
progression. Functional and structural MRI data contribute to a sub-
stantial, but still partial, understanding of PD pathophysiology. In order
to enhance this knowledge, DTI allows the study of white fiber in-
tegrity, which is also impacted by the neurodegenerative processes.
1.2. Diffusion tensor imaging to understand PD pathophysiology
DTI is an approach used to estimate changes in white matter in-
tegrity, which makes it possible to study the structure of cerebral tissue,
such as the trajectories in white matter bundles and the orientation of
fibers (Conturo et al., 1999; Mori et al., 1999). It is based on the
measurement of “the random motion of water molecules in fluid water”
(Stieltjes et al., 2012), particularly suited to neural fibers (Le Bihan,
2003). Two crucial measures that can be used are the mean diffusivity
(MD) and the fractional anisotropy (FA) (Basser and Pierpaoli, 1996).
MD refers to the diffusion of water molecules in organic tissues. In-
creased MD can be problematic since it indicates that the tissues do not
retain water molecules, possibly because of an enlargement of the ex-
tracellular space, suggesting degeneration of the tissue (Syková, 2004).
FA characterizes the orientation distribution of the random movement
of water molecules. Anisotropy refers to a non-uniform diffusion of
water molecules in tissues. The closer to 1 the FA value is, the more
anisotropic this diffusion is. Conversely, for an FA value close to 0, the
movement of water molecules would be isotropic, suggesting damaged
tissue when measured in white matter (Schulte et al., 2005). In other
words, FA and MD make it possible to measure demyelination as a sign
of white matter alteration (Song et al., 2002); while this is generally
accepted, changes in FA or MD values can be explained by other cellular
changes unrelated to white-matter integrity, or by crossing fibers (Alba-
Ferrara and de Erausquin, 2013; Jeurissen et al., 2013). FA and MD
have been used as markers of structural damage in some pathologies
(e.g. for a review of mild cognitive impairment and Alzheimer's disease:
Sexton et al., 2011; epilepsy: Otte et al., 2012; depression: Wen et al.,
2014; amyotrophic lateral sclerosis: Foerster et al., 2013). DTI can also
be used to study structural changes induced by training (Sagi et al.,
2012; Engvig et al., 2012) and has been hypothesized to reveal com-
pensatory reorganization of specific areas in certain pathologies for
human (Yu et al., 2016) and animal models (Ding et al., 2008). DTI
holds promise for contribution to the differential diagnosis between PD
and atypical Parkinsonian syndromes (for reviews, see Cochrane and
Ebmeier, 2013; Meijer et al., 2013; Seppi and Poewe, 2010). Since the
Fig. 1. Study selection for the meta-analysis.
*No data available: for these studies, the means and stan-
dard deviations of FA and MD, for healthy controls and PD
patients, were not directly available in the articles.
**Surgical studies: these articles involved PD patients with
brain lesions.
C. Atkinson-Clement et al. NeuroImage: Clinical 16 (2017) 98–110
99
early 2000s, the number of comparative studies between PD individuals
and healthy controls has been growing.
Concerning PD, previous reviews and meta-analyses focused on the
differential diagnosis between PD and atypical Parkinsonian syndromes
(see Cochrane and Ebmeier, 2013; Meijer et al., 2013; Seppi and Poewe,
2010) and the comparisons between PD patients and healthy controls in
the SN (Schwarz et al., 2013). This focus on the SN represents so far the
main consensual information related to DTI exploration of PD neuro-
degenerative processes. Actually, despite recent literature reviews on
DTI (Hall et al., 2016) and fMRI resting state (Prodoehl et al., 2014),
and unlike for VBM (e.g., Pan et al., 2012), a whole-brain meta-analysis
for DTI in PD was not available so far. Considering PD neurodegen-
eration of both cortical and sub-cortical structures is of particular in-
terest since it would contribute to understand PD pathophysiology from
a more global perspective. Our objective in this article is to provide this
missing meta-analysis in order to further reinforce knowledge on PD
pathophysiology, to address the heterogeneities in the literature, and
identify convergence of findings.
2. Methods
2.1. Literature search
To identify the articles for our literature review, we searched for
publications on the Medline®/PubMed database (http://www.ncbi.nlm.
nih.gov/pubmed/), without any temporal restriction. To run our
search, the keyword ‘Parkinson’ was associated with the following
terms: ‘diffusion tensor imaging’, ‘tractography’, ‘fractional anisotropy’ and
‘mean diffusivity’. After excluding duplicates (n = 181) and in-
appropriate articles (n = 177), we retained for analysis 39 relevant
studies published between 2006 and 2016, reporting original research
(editorials, letters to editors, discussions and reviews were excluded)
with exploitable data (Fig. 1). In total, data from 1855 individuals were
considered in this review: 1087 PD patients and 768 healthy in-
dividuals. Among the 39 articles, we retained 38 studies for the FA
analysis and 25 for the analysis of MD. We considered only the studies
reporting the FA and/or the MD, since other indicators (such as axial
and radial diffusivity) were less reported in the literature and that the
number of data was insufficient to perform a meta-analysis. Tracto-
graphy studies have not been included in our analysis: although trac-
tography is increasingly being used to map fiber pathways relevant to
PD (Pujol et al., 2017), it is quite complicated in terms of methodology
and its accuracy is still debated (Thomas et al., 2014).
2.2. Main variables
Among the 39 articles selected, we extracted the values (means and
standard deviations) of FA and/or MD directly available and for each
region specified in the selected publications. From these data, we
considered two levels of classification of brain regions. The first one, so-
called “anatomical level”, referred to the specific regions reported in the
selected publications (e.g. SN; caudate nucleus; olfactory regions). The
second one corresponded to the “clustering level” that we generated by
gathering together the anatomical regions of the first level: 4 clusters
were then identified, namely cortical, subcortical, white fiber, and
cerebellum.
The quantitative statistical meta-analysis was performed using the
OpenMeta[Analyst] software (MetaAnalyst, Tufts Medical Center
(Wallace et al., 2012)). This software is a visual front-end for the R
package (www.r-project.org; Metafor; Viechtbauer, 2010). We used this
software with default parameters for comparing two participant groups
(PD individuals vs. healthy controls). As the main variables for our
meta-analysis, results from the different studies were considered on the
basis of the disease effect size (DES) to account for inter-study hetero-
geneity (e.g., demographic, clinical, and technical information). In this
context, the DES corresponds to a standardized effect size, Z-scored,
which considers the difference in standard deviations between PD pa-
tients and healthy controls, both for FA (FA-DES) and MD (MD-DES). The
DES score was calculated using the Hedges' g corresponding to the fol-
lowing calculation:
=
−
∗
D Mean PD Mean HC
SES
where S* represents the pooled standard deviation of the two groups. In
addition, as implemented within the software OpenMeta[Analyst], the
DES scores were corrected for a slight positive bias within the function
(Hedges and Olkin, 1985; Viechtbauer, 2010).
Following this calculation, fiber degradation in PD is expected to be
associated with negative FA-DES scores and positive MD-DES scores;
conversely, positive FA-DES scores and negative MD-DES scores should
refer to brain reorganization. Calculations were based on a random
effect model using DerSimonian and Laird's method, for which the ef-
fects are supposed to vary between studies (Borenstein et al., 2009).
The statistical significance level for FA-DES and MD-DES was set at
p < 0.05 in our analyses.
2.3. Co-variables
For our analyses, we were also interested in participant demo-
graphic and clinical characteristics, if available, such as the gender and
age of all individuals, as well as the disease duration of PD patients
(Table 1A). We did not consider the motor scores of the UPDRS - Uni-
fied Parkinson's Disease Rating Scale (Fahn et al., 1987) - because they
were not available for all studies, and because the medication state of
the PD patients varied across studies (18 studies with patients under
medication, 8 without medication, and 12 without this information).
We also considered MRI acquisition parameters (field strength [T];
voxel size [mm3]; number of directions for the DTI; echo time [TE];
repetition time [TR]; Bihan factor [b]; Table 1B) as co-variables.
2.4. Statistical analyses
Heterogeneity in a meta-analysis refers to the variation in outcomes
between studies. The usual measure of heterogeneity is Cochran's Q,
which is calculated as the weighted sum of squared differences between
individual study effects and the pooled effect across studies. Cochran's
Q test provides a p-value, with low p-values highlighting the presence
of heterogeneity between studies without any size estimate. To improve
the interpretation of our analyses, we also calculated the heterogeneity
index (I2). This measure can be interpreted as the proportion of total
variability explained by heterogeneity and refers to the percentage of
variation across studies (Higgins et al., 2003). I2 can be calculated from
Q statistic (100% × [Q− degrees of freedom] / Q) and does not de-
pend on the number of studies included in the meta-analysis. Thus, I2
highlights the inconsistency across studies and ranges from 0% (i.e. no
heterogeneity) to 100% (i.e. the highest heterogeneity). Heterogeneity
can be considered as low (0 < I2 < 30%), moderate
(30 < I2 < 60%), substantial (50 < I2 < 90%) or considerable
(75 < I2 < 100%). The statistical significance level for I2 was set at
p < 0.05 in our analyses.
We used three different R packages in order to conduct Pearson's
correlations (Rcmdr package) to analyse the relationship between the
main variables (FA-DES and MD-DES) and several co-variables that are
detailed above; graphical representations were performed using Hmisc
and Corrplot R packages. In a second step, we have performed a Holm's
correction for multiple correlation. The statistical significance level for
the correlations was set at p < 0.05. FA-DES and MD-DES were reported
according to four anatomical regions: 1) subcortical nuclei; 2) white
matter; 3) cortical areas; and 4) cerebellar regions. Thus, the FA-DES
and MD-DES were generated by compiling together each value, from
each study, of all regions included in the 4 brain territories that we pre-
defined.
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Table 1A
Demographic and clinical information of studies involved in meta-analysis.
N Study Group Participants Gender (F/
M)
Mean age ± SD (years) Mean UPDRS-III ± SD [on/off L-Dopa] Mean disease duration ± SD (years)
1 Blain et al. (2006) PD 12 6/6 65.1 ± 7.3 22.2 ± 9.9 [on] 6.9 ± 2
HC 12 7/5 63.4 ± 6.3 – –
2 Matsui et al.
(2006)
PD 26 23/3 71.2 ± 9.2 31.4 ± 17.6 [on] 8.7 ± 5.5
PD - sleepiness 11 8/3 72.2 ± 7.2 42.2 ± 11.2 [on] 9.6 ± 5
HC 10 7/3 72.4 ± 6.4 – –
3 Matsui et al.
(2007)
PD 26 22/4 70 ± 8.6 30.1 ± 14.4 [on] 8.3 ± 5.6
PDD 11 9/2 75 ± 7.7 45.3 ± 17 [on] 10.5 ± 4.3
HC 10 na 70.7 ± 17.4 – –
4 Ito et al. (2008) PD 29 na 67 ± 9 na [na] 4.8 ± 3.3
HC 19 na 73 ± 5 – –
5 Gattellaro et al.
(2009)
PD 10 5/5 63.8 ± 15.7 14.2 ± 6.5 [on] 3.4 ± 2.9
HC 10 5/5 58.1 ± 8 – –
6 Boelmans et al.
(2010)
PD 14 7/7 57.9 ± 7.7 19.5 ± 7.2 [na] 2.9 ± 1.56
HC 14 8/6 58.6 ± 10.6 – –
7 Menke et al.
(2010)
PD 10 3/7 63.7 ± 6.7 na [on] na
HC 10 3/7 64.4 ± 9.9 – –
8 Peran et al. (2010) PD 30 10/20 61.9 ± 11.1 12 ± 5.9 [on] 4.5 ± 2.5
HC 22 11/11 57.4 ± 9.7 – –
9 Wiltshire et al.
(2010)
PD 29 12/17 70.8 ± 4.6 16.8 ± 7.6 [na] na
PDD 6 1/5 71.4 ± 4.2 19.5 ± 8.5 [na] na
HC 15 7/8 70.7 ± 4 – –
10 Rolheiser et al.
(2011)
PD 14 6/8 56 ± 4.8 na [on] 2.5 ± 1.76
HC 14 6/8 55.2 ± 6.2 – –
11 Carlesimo et al.
(2012)
PD 25 7/18 65 ± 8.4 18.6 ± 8.7 [on] 4.4 ± 4
HC 25 7/18 65 ± 8.9 – –
12 Du et al. (2012) PD - early 15 8/7 60.2 ± 10.1 17.1 ± 9.4 [off] 0.5 ± 0.5
PD - mild 14 6/8 59.2 ± 6 21.6 ± 11 [off] 3.3 ± 1.1
PD - later 12 3/9 63.4 ± 7.9 34.6 ± 20.3 [off] 10.4 ± 4.3
HC 28 15/13 59.8 ± 7 – –
13 Kamagata et al.
(2012)
PD 15 6/9 69.8 ± 5.9 19 ± 12 [on] 5.88 ± 4.8
PDD 15 7/8 71.3 ± 5.6 27.1 ± 9.9 [on] 11.58 ± 8.04
HC 15 9/6 69.5 ± 6.9 – –
14 Prakash et al.
(2012)
PD 11 7/4 60.4 ± 9.3 23.5 ± 9.5 [off] 5.7 ± 4.2
HC 12 6/6 60.8 ± 8.5 – –
15 Surdhar et al.
(2012)
PD 6 1/5 68.59 ± 2 11.83 ± 2.5 [na] na
PD -
depression
6 1/5 70.95 ± 2.9 16.67 ± 11.6 [na] na
HC 6 1/5 70.69 ± 2.4 – na
16 Zhan et al. (2012) PD 12 0/12 67.4 ± 8 26.3 ± 12.2 [off] na
HC 20 0/20 67.2 ± 8 – na
17 Deng et al. (2013) PD 24 14/10 62.1 ± 8.6 30.2 ± 12.2 [na] 4.7 ± 3.4
PD - MCI 30 15/15 65.1 ± 11.8 42.4 ± 14 [na] 5.1 ± 2.9
PDD 10 5/5 69 ± 9.7 56 ± 15.3 [na] 6.8 ± 6.86
HC 21 10/11 60.1 ± 13.6 – –
18 Kamagata et al.
(2013a)
PD 17 8/9 65 ± 9.3 na [on] 6.7 ± 4.6
HC 15 5/10 64 ± 12.7 – –
19 Kamagata et al.
(2013b)
PD 20 12/8 71.6 ± 4.3 na [on] 7.8 ± 4.45
PDD 20 10/10 71.7 ± 5.3 na [on] 12.2 ± 7.58
HC 20 10/10 72.7 ± 3.3 – –
20 Ota et al. (2013) PD 21 11/10 62.2 ± 7 na [na] 6.8 ± 4.1
HC 21 10/11 62.3 ± 5.6 – –
21 Prodoehl et al.
(2013)
PD 15 2/13 62.7 ± 7.7 30 ± 8.9 [off] 10.5 ± 7.3
HC 17 7/10 62.9 ± 9 – –
22 Scherfler et al.
(2013)
PD 16 10/6 68.1 ± 6.1 20 ± 10.3 [off] 3.7 ± 3.7
HC 14 8/6 67.3 ± 3.7 – –
23 Schwarz et al.
(2013)
PD 32 16/16 64.8 ± 11.8 26.1 ± 13.9 [on] na
HC 27 16/11 59.9 ± 10.5 – –
24 Baudrexel et al.
(2014)
PD 13 5/8 66.8 ± 8 41 ± 11.1 [na] 6.4 ± 6)
HC 6 1/5 65.3 ± 10.8 – –
25 Chan et al. (2014) PD 21 4/17 72 ± 4.8 na [on] na
PD - gait
disorder
25 7/18 73.3 ± 6.2 na [on] na
HC 19 3/16 71.5 ± 5 – –
26 Kamagata et al.
(2014)
PD 12 6/6 65.4 ± 10 na [on] 7.1 ± 4.5
HC 10 5/5 67.6 ± 10.1 – –
27 Menke et al.
(2014)
PD 20 9/11 60 ± 11 24.9 ± 10 [on] 1.8 ± 0.8
HC 20 9/11 60 ± 8 – –
28 Jiang et al. (2015) PD 31 15/16 69.4 ± 8 na [na] na
HC 34 16/18 69.3 ± 8 – –
29 Mormina et al.
(2015)
PD 16 8/8 62.2 ± 8.6 21 [na] 11.1 ± 4.5
HC 16 9/7 60.1 ± 7.2 – –
30 Skidmore et al.
(2015)
PD 20 3/17 64 ± 9 34 ± 14 [na] na
HC 22 8/14 61 ± 13 – –
(continued on next page)
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We do not discuss the data when FA-DES and MD-DES were reported
by only one study, or when DES was significant only for FA or MD and
significantly heterogeneous (I2).
2.5. Subset analysis of medication effects on SN
We performed a specific analysis on the effect of dopaminergic state
on FA-DES and MD-DES for SN. Some studies suggested that dopami-
nergic state can influence the results of functional (e.g., Tessitore et al.,
2012; Krajcovicova et al., 2012) and anatomical (Salgado-Pineda et al.,
2006) MRI acquisition. However, “the effects of medication on DTI are not
known” (Prodoehl et al., 2013). It is conceivable that medication states
played a role and contributed to the results of the DTI analyses. To test
this hypothesis on the data involved in our study, we ran an additional
meta-analysis that considered only the SN, and that separated off- and
on-medication data for FA-DES and MD-DES.
3. Results
3.1. Demographic and clinical characteristics
Demographic and clinical information available in the studies se-
lected are summarized in Table 1A. The gender distribution was highly
heterogeneous for both PD patients (women proportion = 0.43, ran-
ging from 0 to 0.88 across studies; 95% confidence in-
terval = 0.36–0.49; I2 = 79.9%; p < 0.001) and healthy controls
(women proportion = 0.42, ranging from 0 to 0.7; 95% confidence
interval = 0.34–0.49; I2 = 81%; p < 0.001). When comparing PD
patients with healthy controls, the numbers of men and women were
similar across studies (odds ratio = 0.96; 95% confidence in-
terval = 0.79–1.16; I2 = 0%; p = ns). The mean age was similarly
heterogeneous for PD patients (range = 56–75 years; mean = 66.19;
95% confidence interval = 64.97–67.42; I2 = 89%; p < 0.001) and
for healthy controls (range = 55–73 years; mean = 64.87; 95% con-
fidence interval = 63.25–66.50; I2 = 91%; p < 0.001). The compar-
ison between PD patients and controls was neither significant (p = ns)
nor heterogeneous (I2 = 0%; p = ns). The disease duration displayed
high heterogeneity for PD patients (range = 0.5–12.2 years;
mean = 6.08; 95% confidence interval = 5.32–6.85; I2 = 96.9%;
p < 0.001).
3.2. MRI acquisition parameters
MRI acquisition parameters available in the studies selected are
summarized in Table 1B. The parameters were highly variable, and
some heterogeneity was observed for the voxel size (range: from
0.86 × 0.86 × 3 to 3.4 × 3.4 × 3 mm3), the number of directions
(range: from 6 to 75 directions), and the field strength (range: from 1.5
to 4 T). Moreover, the b factor values (range = 800–2800), the echo
time (range = 55–116) and the repetition time (range = 900–17,300)
were also highly heterogeneous.
3.3. Disease effect size (DES)
At the clustering level (Table 2), significant differences in FA-DES
and MD-DES were found between PD patients and healthy controls in
subcortical and cortical areas. In white matter, this was also the case for
FA-DES only, and no significant differences were found in the cere-
bellum. MD-DES was highly heterogeneous in all significant clusters
except in cortical areas (I2 = 34.5%).
At the anatomical level (Table 2), five regions demonstrated sig-
nificant differences between PD patients and healthy controls for both
FA-DES and MD-DES. Four of these regions showed a decrease of FA-DES
and an increase of MD-DES: the SN, the corpus callosum, the cingulate
and the temporal cortices. The remaining region, localised in the cor-
ticospinal tract, showed an opposite change, that is increased FA-DES
and decreased MD-DES. All regions were heterogeneous for the FA-DES,
but only the corpus callosum was heterogeneous for the MD-DES
(I2 = 52.1%). A single region with a significant difference between PD
patients and healthy controls was found for FA-DES only, in the caudate
nucleus (increased FA-DES). For the MD-DES only, 4 areas (the putamen,
the pallidum, the internal and external capsules, and the olfactory
cortex) displayed significant differences between PD patients and con-
trols (Fig. 2). None of these regions was associated with any significant
Table 1A (continued)
N Study Group Participants Gender (F/
M)
Mean age ± SD (years) Mean UPDRS-III ± SD [on/off L-Dopa] Mean disease duration ± SD (years)
31 Vercruysse et al.
(2015)
PD 15 4/11 67.6 ± 5.6 32.5 ± 9.1 [on] 7.6 ± 5.3
PD - FOG 11 3/8 68.6 ± 8.7 36.6 ± 18.3 [on] 9.5 ± 3.7
HC 15 4/11 68.1 ± 6.5 – –
32 Zhang et al.
(2015a)
PD 50 18/32 59.7 ± 9.2 21.9 ± 7.8 [na] na
HC 27 6/21 56.8 ± 10.7 – –
33 Zhang et al.
(2015b)
PD 72 46/26 66.8 ± 5.4 14.9 ± 3.9 [off] 1.1 ± 0.6
HC 72 44/28 66.1 ± 6.8 – –
34 Kamagata et al.
(2016)
PD 58 26/32 68.8 ± 7.5 18 ± 8.5 [on] 7.4 ± 4.4
HC 36 18/18 70.8 ± 8.4 – –
35 Lee et al. (2016) PD 14 9/5 66.1 ± 6.1 20.3 ± 7.8 [na] 7.3 ± 3.7
PD – VH 10 3/7 69.2 ± 5.2 22.9 ± 5.1 [na] 7.2 ± 3.7
HC 15 8/7 68.5 ± 6.6 – –
36 Lim et al. (2016) PD 14 6/8 69.7 ± 7.2 22.4 ± 10.6 [na] 4.4 ± 3.7
PD – RBD 24 12/12 69.8 ± 6.4 12.4 ± 2.5 [na] 6.2 ± 2.9
HC 25 12/13 68.5 ± 6.6 – –
37 Loane et al.
(2016)
PD – early 18 6/12 56.8 ± 6.8 26.2 ± 9.2 [off] 3.9 ± 2.2
PD – mild 18 6/12 58.3 ± 6.8 34.6 ± 12.5 [off] 5.5 ± 2.2
HC 14 4/10 56.3 ± 6.4 – –
38 Nagae et al.
(2016)
PD 21 9/12 61.1 ± 7.7 31.4 ± 10 [off] 5.5 ± 3.4
HC 20 9/11 61.1 ± 9 – –
39 Price et al. (2016) PD 40 8/32 67.8 ± 5.4 17.6 ± 10.7 [on] 7.5 ± 5.1
HC 40 7/33 68.2 ± 4.6 – –
1087 PD Min–Max 475/584 56–75 11.83–56 0.5–12.2
768C 321/418 55.2–73 – –
N: study; y: years; UPDRS: Unified Parkinson's Disease Rating Scale (III: motor scale); PD: Parkinson's disease; HC: healthy control; PDD: Parkinson's disease with dementia; Dep:
depression; MCI: mild cognitive impairment; FOG: freezing of gait; VH: visual hallucination; RBD: Rapid Eye Movement sleep behavior disorders; [on]/[off]: with/out dopaminergic
treatment; na: not available.
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heterogeneity of DES.
3.4. Correlations between the main variables (FA-DES and MD-DES) and the
clinical, demographic and MRI parameter co-variables
Demographic and clinical variables displayed correlations with the
MD-DES of our meta-analysis (Fig. 3): The results in white matter was
influenced by a gender effect (R = 0.93; p = 0.002), as well as the
disease duration (R =−0.73; p = 0.03).
MRI parameters were also highly correlated with DES (Fig. 3). FA-
DES was correlated with the field strength in cerebellum (R =−0.83;
p = 0.043). For MD-DES, the number of DTI directions and the TE were
correlated in white matter (respectively: R =−0.92, p = 0.007;
R =−0.91, p = 0.003) and cortical areas (respectively: R =−0.95,
p = 0.0008; R =−0.82, p = 0.04). In addition, MD-DES was corre-
lated, in white matter, with the field strength (R =−0.88; p = 0.007)
and the TR (R =−0.81; p = 0.03).
3.5. FA-DES and MD-DES in SN are influenced by dopaminergic state
FA-DES and MD-DES in SN, either off- or on-medication, were sta-
tistically significant (p < 0.001; see Fig. 4). When comparing the two
states, we did not observe any difference between off- and on-medica-
tion states for MD-DES (Off: MD-DES = 0.635; On: MD-DES = 0.65), but
a difference was found for FA-DES (Off: FA-DES =−0.737; On: FA-
DES =−0.519). Significant heterogeneity was found only for off-
medication FA-DES (I2 = 67%; p < 0.001). I2 was low for both dopa-
minergic states in MD-DES (I2 < 30%) and moderate for FA in on-
medication (30% < I2 < 60%).
4. Discussion
4.1. Summary of the findings
Our meta-analysis demonstrated that DTI was able to address
structural differences between PD individuals and healthy controls,
particularly in five cerebral regions sensitive to both FA and MD: the
SN, the corpus callosum, the cingulate and temporal cortices, and the
corticospinal tract. This latter region, contrary to the others, was as-
sociated with increased FA-DES and decreased MD-DES, suggesting
possible brain reorganization. Five brain areas were highlighted by only
one of the two indicators, either FA-DES or MD-DES: the putamen, the
pallidum, the internal and external capsules, and the olfactory cortex,
which showed tissue lesions in PD patients compared with controls.
This was not the case for the caudate nucleus, for which FA-DES sug-
gested a specific reorganization of this nucleus. Therefore, we observe
an effect of the medication state in SN for FA-DES, but not for MD-DES.
Regarding the correlation results, FA-DES was less dependent on co-
variables than MD-DES, particularly for white matter. In the following,
since cerebellar areas did not show any difference in FA-DES or MD-DES
between individuals with PD and healthy controls, we discuss our re-
sults regarding the remaining 3 pre-defined anatomical regions:
Table 1B
Technical data of studies involved in meta-analysis.
N Study Total participants Field strength (T) b value TE TR Acquisition voxel size (mm3) Number of directions FA MD
1 Blain et al. (2006) 24 1.5 1300 107 4000 1.875 × 1.875 × 2.5 60 √ √
2 Matsui et al. (2006) 47 1.5 1000 96.2 8000 1.875 × 1.875 × 4 6 √
3 Matsui et al. (2007) 47 1.5 1000 96.2 8000 1.875 × 1.875 × 4 6 √
4 Ito et al. (2008) 48 1.5 1000 96.4 13,000 2.03 × 1.625 × 5 ns √
5 Gattellaro et al. (2009) 20 1.5 1000 79 4200 1.875 × 1.875 × 2.5 12 √ √
6 Boelmans et al. (2010) 28 1.5 1000 70 10,000 2.1875 × 2.1875 × 3 12 √ √
7 Menke et al. (2010) 20 3 1000 94 9300 2 × 2 × 2 60 √ √
8 Peran et al. (2010) 52 3 1000 89 8500 1.8 × 1.8 × 1.8 30 √ √
9 Wiltshire et al. (2010) 50 1.5 1000 88 5600 0.86 × 0.86 × 3 6 √ √
10 Rolheiser et al. (2011) 28 1.5 900 72 12,000 2.03 × 2.03 × 3 31 √ √
11 Carlesimo et al. (2012) 50 3 1000 89 8500 1.8 × 1.8 × 1.8 30 √
12 Du et al. (2012) 69 3 1000 82 8300 2 × 2 × 2 42 √
13 Kamagata et al. (2012) 45 3 1000 70 5443 2 × 2 × 3 32 √ √
14 Prakash et al. (2012) 23 3 800 60 4500 0.9 × 0.9 × 3 12 √
15 Surdhar et al. (2012) 18 1.5 1000 88 5600 1.7 × 1.7 × 3 6 √ √
16 Zhan et al. (2012) 32 4 1000 77 6000 2 × 2 × 3 6 √ √
17 Deng et al. (2013) 85 3 1000 87.9 12,000 3.4 × 3.4 × 3 16 √
18 Kamagata et al. (2013a) 32 3 2000 70 7041 3 × 3 × 3 20 √ √
19 Kamagata et al. (2013b) 60 3 1000 70 5443 1.75 × 1.75 × 3 32 √ √
20 Ota et al. (2013) 42 1.5 1000 106 11,200 2.5 × 2.5 × 2.5 64 √
21 Prodoehl et al. (2013) 32 3 1000 82 4500 1.33 × 2 × 4 8 √ √
22 Scherfler et al. (2013) 30 1.5 1000 94 6000 1.8 × 1.8 × 3 6 √ √
23 Schwarz et al. (2013) 59 3 1000 60 7415 1 × 1 × 2 32 √ √
24 Baudrexel et al. (2014) 19 3 1000 95 9300 2 × 2 × 2 60 √ √
25 Chan et al. (2014) 65 3 1000 86 8200 1.875 × 1.875 × 2 30 √
26 Kamagata et al. (2014) 22 3 2000 70 7041 3 × 3 × 3 20 √ √
27 Menke et al. (2014) 40 3 1000 94 9300 2 × 2 × 2 60 √ √
28 Jiang et al. (2015) 65 3 1000 87.6 8500 1.846 × 1.875 × 5 30 √
29 Mormina et al. (2015) 32 3 1000 87 6919 2 × 2 × 2.5 60 √
30 Skidmore et al. (2015) 42 3 1000 55 11,304 2 × 2 × 2 32 √
31 Vercruysse et al. (2015) 41 3 2800 116 8700 2.5 × 2.5 × 2.5 75 √ √
32 Zhang et al. (2015a) 77 3 1000 88 900 2 × 2 × 2 64 √
33 Zhang et al. (2015b) 144 3 1000 76.4 6000 1.875 × 1.875 × 5 25 √
34 Kamagata et al. (2016) 94 3 2000 80 4000 0.982 × 0.982 × 5 32 √ √
35 Lee et al. (2016) 39 3 800 66 6598.2 1.964 × 1.964 × 2 ns √ √
36 Lim et al. (2016) 63 3 800 66 6598.2 2 × 2 × 2 ns √ √
37 Loane et al. (2016) 50 3 1000 88 9300 1.875 × 1.875 × 1.9 64 √ √
38 Nagae et al. (2016) 41 3 1000 92 16,000 2.031 × 2.031 × 2 32 √ √
39 Price et al. (2016) 80 3 1000 81 17,300 1 × 1 × 1 70 √
N= 1855 Min 1.5 800 55 900 0.86 × 0.86 × 3 6 38 25
Max 4 2800 116 17,300 3.4 × 3.4 × 3 75
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subcortical nuclei (SN, putamen, pallidum and caudate nucleus), cor-
tical areas (cingulate, temporal, olfactory) and white matter (corpus
callosum and corticospinal tract). We do not discuss the data when FA-
DES and MD-DES were reported by only one study, or when DES was
significant only for FA or MD and significantly heterogeneous. Finally,
we consider the information about clinical and MRI parameters as po-
tential limitations of our analyses in order to further interpret our
findings.
4.2. Pathophysiological and clinical implications of our findings
4.2.1. Subcortical nuclei
Changes in FA and/or MD in the SN due to PD is a controversial
issue: no differences for both FA and MD, as well as an increase in FA,
were reported (Menke et al., 2010; Wang et al., 2011), while other
studies reported decreases in FA in the SN (Chan et al., 2007; Chan
et al., 2014; Du et al., 2011, 2012; Jiang et al., 2015; Peran et al., 2010;
Prakash et al., 2012; Prodoehl et al., 2013; Rolheiser et al., 2011;
Vaillancourt et al., 2009; Yoshikawa et al., 2004; Ota et al., 2013; Youn
et al., 2015; Zhan et al., 2012; Zhang et al., 2015a) and/or increases in
MD (Du et al., 2014; Kamagata et al., 2016; Loane et al., 2016; Nagae
et al., 2016; Scherfler et al., 2013; Schwarz et al., 2013). Moreover,
correlations between PD severity and FA were found both significant
(Chan et al., 2007; Zhan et al., 2012) and not significant (Du et al.,
2011). It has also been shown that FA would be able to distinguish
healthy subjects from de novo PD individuals, especially in the caudal
region of the SN (Vaillancourt et al., 2009). Thus, DTI in the SN should
help to distinguish PD patients from healthy controls, and possibly to
detect individuals susceptible to developing PD: in fact, FA was found
sensitive enough to distinguish healthy controls from controls who have
been exposed to chemicals for about 20 years, and identified as a po-
pulation at risk of developing PD (Du et al., 2014). Our results do not
allow concluding to a possible ability of DTI to track PD progression.
Nevertheless, previous studies reported that DTI (with FA, MD, radial
and axial diffusivity) is able to track progression of the SN long-
itudinally in PD (Loane et al., 2016; Ofori et al., 2015; Zhang et al.,
2016). Moreover, the DTI changes in SN seem to be linked with bra-
dykinesia, cognitive status (Ofori et al., 2015) and dopaminergic deficit
(Zhang et al., 2016). First, the patient movement depending on the
dopaminergic state during scanning (e.g., tremor when “off” or dyski-
nesia when “on”) could be an argument in favour of image acquisition
deterioration. It is also conceivable that medication states induced a
neuroimaging artefact in the form of an increase in gray matter volume
in the midbrain (substantia nigra, tegmental ventral area and sub-
thalamic nucleus) previously reported with VBM (Salgado-Pineda et al.,
2006), but not with DTI (Chung et al., 2017). In fact, levodopa could
have intrinsic magnetic properties that could induce a variation in
signal intensity and lead to a misclassification of voxels as part of gray
or white matter. The interaction of dopaminergic treatments with iron
(chelation or binding) could also partly explain this effect (Campbell
and Hasinoff, 1991). Previous meta-analyses did not take this effect into
account (Cochrane and Ebmeier, 2013; Schwarz et al., 2013), and fu-
ture studies should pay attention to medication states, particularly for
the investigation in the SN, as a precaution principle.
Table 2
Disease effect size (DES) and heterogeneity index (I2) for FA and MD according to the subcortical, white matter, cortical and cerebellar regions.
FA MD
Nstudies Ndata DES (p-value) I2 (p-value) Nstudies Ndata DES (p-value) I2 (p-value)
Cluster 1 - subcortical 20 72 −0.245⁎⁎ 82.6%⁎⁎⁎ 15 49 0.381⁎⁎⁎ 63.1%⁎⁎⁎
Substantia nigra 16 30 −0.706⁎⁎⁎ 75.9%⁎⁎⁎ 10 16 0.635⁎⁎⁎ 23.5%
Putamen 10 16 0.273 85.2%⁎⁎⁎ 7 11 0.338⁎⁎⁎ 0%
Thalamus 5 10 −0.320 80.9%⁎⁎⁎ 5 11 0.260 64.6%⁎⁎
Caudate nucleus 4 7 0.406⁎⁎⁎ 0% 4 6 −0.159 91.1%⁎⁎⁎
Pallidum 3 4 −0.270 53% 3 4 0.533⁎⁎ 0%
Pedonculopontine nucleus 1 4 0.029 0%
Red nucleus 1 1 0.332(NA) NA(NA) 1 1 0.780(NA) NA(NA)
Cluster 2 - white matter 17 104 −0.148⁎ 71.6%⁎⁎⁎ 12 106 0.041 42.3%⁎⁎⁎
Corpus callosum 8 46 −0.188⁎⁎ 31.1%⁎ 5 32 0.262⁎ 52.1%⁎⁎⁎
Corticospinal tract 4 17 0.531⁎ 89.8%⁎⁎⁎ 3 48 −0.156⁎⁎ 4.9%
Fasciculus longitudinal 3 9 −0.028 50.8%⁎ 1 1 0.751(NA) NA(NA)
Capsules 2 6 −0.631 84.4%⁎⁎⁎ 2 6 0.311⁎ 0%
Cingulum 2 3 −0.362 61.8% 2 3 0.316 20.9%
Pons 2 3 0.419 56.2% 1 1 0.041(NA) NA(NA)
Corona radiate 2 3 0.011 0% 2 3 0.221 68.1%⁎
Optic tract 1 8 −0.659⁎⁎⁎ 26.8% 1 8 −0.03 74.4%⁎⁎⁎
Fasciculus uncinate 1 4 −0.164 0% 1 4 0.070 0%
Fornix 1 2 −2.169⁎⁎ 74.7%⁎
Centrum semiovale 1 2 0.052 0%
Nigrostriatal tract 1 1 −0.297(NA) NA(NA)
Cluster 3 - cortical 10 89 −0.740⁎⁎⁎ 75.7%⁎⁎⁎ 6 18 0.418⁎⁎⁎ 34.5%
Frontal 7 22 −0.774⁎⁎⁎ 79.7%⁎⁎⁎ 2 8 0.179 55%⁎
Cingulate 4 25 −0.486⁎⁎⁎ 66.5%⁎⁎⁎ 1 4 0.509⁎⁎ 1.1%
Parietal 5 15 −0.648⁎⁎⁎ 47.8%⁎ 1 2 0.500 0%
Temporal 5 14 −1.196⁎⁎⁎ 83.8%⁎⁎⁎ 1 2 0.605⁎⁎ 0%
Occipital 3 12 −0.694⁎⁎ 78.5%⁎⁎⁎
Olfactory 1 1 −2.699(NA) NA(NA) 2 2 0.848⁎⁎ 0%
Cluster 4 - cerebellum 5 17 −0.246 80.4%⁎⁎⁎ 3 5 0.128 39.6%
Cerebellar peduncle 5 10 −0.094 77.2%⁎⁎⁎ 1 2 0.324 0%
Cerebellum 2 7 −0.468 84.4%⁎⁎⁎ 2 3 0.026 65.2%
All 38 282 −0.363⁎⁎⁎ 78.3%⁎⁎⁎ 25 182 0.182⁎⁎⁎ 54%⁎⁎⁎
DES: disease effect size; FA: fractional anisotropy; MD: mean diffusivity; I2: heterogeneity index; Ndata: number of data included; Nstudies: number of different studies included. NA:
insufficient number of data to perform statistical analysis.
Regions that have a significant effect size for FA or MD are highlighted in bold.
⁎ p < 0.05.
⁎⁎ p < 0.01.
⁎⁎⁎ p < 0.001.
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Fig. 2. Brain areas identified following the meta-analysis and associated with significant differences between PD patients and healthy controls for FA-DES and MD-DES, performed together
or separately.
The framed results correspond to an opposite pattern of results (i.e. FA-DES increase and MD-DES decrease for the corticospinal tract; FA-DES increase for the caudate nucleus).
Fig. 3. Significant positive (red) and negative (blue) correlations
between the main variables (FA-DES and MD-DES) and the se-
lected co-variables, according to the pre-defined anatomical
clusters.
How to read this figure? For example: in cortical areas, there is a
positive correlation between the FA-DES and the voxel size used
for the MRI acquisition of the DTI and in white matter, there is a
negative correlation between the MD-DES and the age of the
participants. The larger the dot, the stronger the correlation. (For
interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article.)
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Regarding the putamen and the pallidum, our analysis showed a
significant increase in MD-DES, as already demonstrated (Menke et al.,
2014; Nagae et al., 2016) and supporting the idea of a degeneration of
the pallidum in PD patients compared with controls (Rajput et al.,
2009). This result is still a matter of debate since previous DTI studies
also failed to detect such differences in the putamen (Gattellaro et al.,
2009; Peran et al., 2010; Loane et al., 2016; Nagae et al., 2016) and the
pallidum (Gattellaro et al., 2009), even suggesting that the pallidum
can be spared in PD (Gattellaro et al., 2009). DTI of the putamen and
pallidum does not seem particularly discriminating and using other DTI
indexes (e.g., orientation dispersion index, longitudinal diffusivity)
could be helpful to provide significant differences in these subcortical
regions (Kamagata et al., 2016; Prodoehl et al., 2013).
The caudate nucleus was associated with significantly increased FA-
DES for PD patients compared with healthy controls, but with no change
in MD-DES (Gattellaro et al., 2009; Jiang et al., 2015; Loane et al., 2016;
Nagae et al., 2016; Prodoehl et al., 2013). This increase would reveal a
selective neurodegeneration, reflecting much likely some gliosis (Budde
et al., 2011) as already reported in Parkinsonian syndromes (Planetta
et al., 2016). One can also imagine an alternative interpretation that
would lead to consider a potential compensatory reorganization pre-
viously reported using functional connectivity (Hou et al., 2016).
However, some studies also reported degeneration of the caudate nu-
cleus using VBM (Reetz et al., 2009; Watanabe et al., 2013; Zhang et al.,
2014; Ellfolk et al., 2013; Herman et al., 2014; Kostic et al., 2012;
O'Callaghan et al., 2014) or DTI (e.g., Menke et al., 2009; Wang et al.,
2011; Rossi et al., 2014). These latter studies were not included in our
meta-analysis, since they did not fulfil the inclusion criteria: DTI in-
vestigation of the caudate nucleus requires further studies in order to
draw robust conclusions on this point. Post-mortem observations could
be an option to objectify possible reorganization of this nucleus.
4.2.2. Cortical areas
In general, our meta-analysis showed that the DES in cortical regions
were highly heterogeneous for FA. More specifically, the DES of the
temporal and cingulate cortices displayed a significant increase in MD
and a significant decrease in FA. While PD patients without cognitive
decline present no FA changes in temporal regions when compared with
healthy controls (Price et al., 2016), temporal cortex degeneration has
been associated with cognitive status decline (Deng et al., 2013;
Carlesimo et al., 2012). Using a classification analysis, superior tem-
poral regions have been shown to be discriminant between healthy
controls and PD (Ota et al., 2013). Similarly, cingulate cortex changes
were correlated to cognitive performance (Kamagata et al., 2012; Zheng
et al., 2014) and can help to discriminate PD patients with dementia
from healthy controls (Deng et al., 2013; Matsui et al., 2007). All these
findings taken together suggest that the cognitive status of PD patients
is principally associated with perceptible damage in the temporal and
cingulate cortices.
For the olfactory cortex, our meta-analysis showed a significant
increase in MD in individuals with PD compared with healthy controls.
In accordance with the Braak model of temporal degeneration in PD,
considering the olfactory cortex as an early degenerative structure
(Hawkes et al., 2007), two studies included in our analysis aimed at
testing the possibility of the structural changes in the olfactory tract
identified by DTI as a biomarker for PD diagnosis (Rolheiser et al.,
2011; Scherfler et al., 2013). In fact, they reported FA and MD changes
between PD patients and healthy controls, and a correlation between
olfactory performance test and motor scores (Rolheiser et al., 2011;
Scherfler et al., 2013). However, these studies did not involve any de
novo PD patients. Another study, using DTI and statistical modelling,
recently suggested that olfactory regions were particularly efficient at
distinguishing de novo drug-naïve PD patients from healthy controls
(Nigro et al., 2016). It is too early to conclude about the sensitivity and
specificity of DTI in olfactory regions as a biomarker of PD, but the
results of our meta-analysis suggest that it could be used by clinicians as
an additional measure.
4.2.3. White matter
MD-DES in white matter was highly correlated with demographic
and clinical data, as well as with MRI parameters. Our analyses dis-
played significant changes in FA-DES (decrease) and MD-DES (increase)
in the corpus callosum. It has been shown that the deterioration of the
corpus callosum genu is linked to PD dementia (Kamagata et al.,
2013b), as well as executive and attention dysfunctions (Zheng et al.,
2014). DTI of the corpus callosum (in the body and the splenium) can
Fig. 4. FA-DES (in pink) and MD-DES (in green) in the Substantia Nigra of PD patients with (On) and without (Off) medication.Each dot corresponds to the Z-scored DES calculated from the
data provided by the selected studies. The more FA dots there are on the left, the smaller the FA is for PD patients compared with healthy controls. DES: disease effect size (Z-scored); FA:
fractional anisotropy; MD: Mean diffusivity.
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help differentiating PD patients according to their cognitive status
(normal, mild cognitive impairment, or dementia; Deng et al., 2013);
for this purpose, MD demonstrated to be more accurate than FA
(Wiltshire et al., 2010). In addition, structural alteration of the corpus
callosum, shown using DTI, seems to be involved in predominant gait
disorders (Chan et al., 2014) and impulse control disorders (Yoo et al.,
2015). Other studies did not observe any change in FA and MD, and did
not report any correlations with clinical assessments (Boelmans et al.,
2010; Ito et al., 2008). The corpus callosum is probably injured in PD,
possibly in advanced stages of PD (Hawkes et al., 2007).
We also observed a significant FA-DES increase and a MD-DES de-
crease in the corticospinal tract, suggesting a reorganization of these
fibers that can be interpreted as either a compensatory mechanism as a
“response to [the] decreased input from the thalamus and striatum”, or a
selective neurodegeneration where increase of FA should be the “con-
sequence of altered pallido-thalamic activity” (Mole et al., 2016). The
increase in FA possibly reflects an increase in axonal density in some
pathways, as the result of axonal sprouting (Arkadir et al., 2014). This is
in line with other previous studies using DTI (Gattellaro et al., 2009;
Kamagata et al., 2012; Deng et al., 2013; Nilsson et al., 2007). Re-
garding the internal and external capsules, a significant increase in MD-
DES was barely observed in our analysis, as previously observed (Zhan
et al., 2012). A correlation between the increase in MD in the internal
capsule and the increase in the UPDRS motor score (Vercruysse et al.,
2015), as well as between FA, MD and gait difficulty (Lenfeldt et al.,
2016), was also reported. Altogether, these findings suggest that de-
generations of the internal and external capsules are possible additional
markers of PD.
4.3. Methodological considerations
Several limitations of our meta-analysis have to be acknowledged,
mainly based on the characteristics of the anatomical structures and the
technical DTI acquisition parameters. Consequently, and more specifi-
cally, the correlations we found should be interpreted with caution. To
a certain extent, they suggested some sensitivity of FA and MD (in
several territories) to other factors, such as demographics, clinical data
and MRI parameters. But it is difficult to draw any robust conclusion
regarding causality relationships between factors. Nevertheless, these
factors should be considered in future research in order to control as
much as possible influences on DTI acquisition.
4.3.1. From an anatomical perspective
DTI results depend on the nature of the structures studied. DTI is
particularly dedicated to the exploration of deep white matter (where
inter-individual variability is restricted), while for the gray matter and
cortico-spinal fluid, the evaluation is more uncertain (Jones, 2008).
Areas with a low FA score (below 0.2) should be interpreted with
caution (generally, these areas are located in the cortex; Marenco et al.,
2006), “because axon and dendrite orientations are not normally
aligned […] in human cortex” (Mori and Zhang, 2006).
4.3.2. From a technical perspective
Many studies aimed at determining the best criteria to limit arte-
facts in DTI acquisition (Gallichan et al., 2010). Tournier et al. (2011)
defined a spatial resolution yielding acceptable artefact reduction:
2 × 2 × 2 mm3, and Viallon et al. (2015) considered that a high spatial
resolution should be fixed at 1 mm3 (particularly for crossing-fiber re-
gions; Oouchi et al., 2007). Moreover, it is recommended to use a 3 T
MRI to reduce the noise (for all tissues), despite a possible increase in
spatial distortions (Alexander et al., 2006). Jones et al. (2013) re-
commended to use at least 30 diffusion directions, in order “to obtain
robust estimates of tensor-derived properties”; Ni et al. (2006) only ob-
served differences of FA between 6, 21 and 31 directions for regions
with low anisotropy (Ni et al., 2006). As much as possible, the use of
parallel image acquisitions (for example, with generalized auto-
calibrating partially parallel acquisition; Griswold et al., 2002) seems to
be recommended. Moreover, the software algorithms used to calculate
DTI parameters could introduce variability, but each software presents
its own strengths and weaknesses (Liu et al., 2015). It is also possible to
use other MR acquisition schemes, for example diffusion spectrum
imaging, to enhance DTI acquisition. This method, with longer acqui-
sition duration than DTI (from 15 to 60 min), makes it possible to
measure fiber crossing (Hagmann et al., 2006). Studies using VBM are
quite numerous, and very informative as well; in order to ensure an
exhaustive and non-invasive study of pathophysiology of PD, com-
bining DTI and VBM analyses represents a very good option that should
be considered when studying PD cortical degeneration.
5. Conclusion
Our meta-analysis aimed at providing a quantitative evaluation of
structural brain changes associated with PD. We showed that DTI is
particularly relevant for subcortical areas (lesions in the SN, the pu-
tamen and the pallidum, and a possible reorganization or a selective
neurodegeneration in the caudate nucleus). It is also informative for
cortical areas and white matter. DTI evaluation of structural lesions
remains difficult, due to the variability in PD pathophysiology and MRI
acquisition parameters (e.g. artefacts and nature of the region of in-
terest). However, our meta-analysis and literature review contributes to
significantly increasing our knowledge of PD pathophysiology. It also
addresses the interesting possibility of follow-up of the disease severity
and associated brain structural modulations using in vivo imaging.
From our review and meta-analysis, we can summarize the following
points: DTI in olfactory regions could participate to the diagnosis of PD;
FA and MD in SN are good indicators to identify PD patients, but also
for PD progression; The corpus callosum degenerates in PD, but with a
high variability; its integrity is correlated to specific symptoms (e.g.,
impulse disorders, gait); The caudate nucleus and cortico-spinal tract
show an increase in FA and decrease in MD but further studies are re-
quired to conclude about the nature of these variations and their pos-
sible link with a degenerative process; As a precaution, PD patients
should be assessed while not under medication; DTI in structures with
non-uniform white fibers organization should be avoided, such as in
cortical regions. Despite some limitations, DTI appears as a sensitive
method to study PD pathophysiology and severity. The association of
DTI with other MRI methods (VBM; generalized autocalibrating par-
tially parallel acquisition; Diffusion Spectrum Imaging) should be
considered to study brain alterations in PD.
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